News & Media Media FEATUREDDefence Therapeutics spotlight on BTV Developing Next Generation Biopharmaceutical Innovations Making a Global Impact News Releases 2023 Defence To Complete A Final Pre-Clinical Study Prior To Ind Filings For The Accutoxtm Phase I Cancer Trial At The City Of Hope National Medical Center And Beckman Research Institute Defence therapeutics announces exercise of warrants for gross proceeds of over $5 million Defence therapeutics signs collaboration agreement with Orano to develop the next generation of targeted radio-immunotherapy for cancer Defence’s Pipeline Advances To Multiple Phase I Clinical Trials Defence Delegates City Of Hope To Initiate Ind Filing For Its Accutox™ Cancer Program Defence Manufacturing Its Arm Vaccine In Preparation For Phase I Clinical Trial Against Solid Tumors Defence’s lung cancer GLP tox study on its intranasal accutox™ formulation advances Defence's Melanoma Targeted Vaccine A1 – Reprogrammed MSC (ARM) Cell Potency Validated Defence’s to Present at the 9th Annual Immuno-oncology 360° Summit in New York February 7–10, 2023 Defence’s Accum™ Accepted US Patent to Bolster its Vaccine Platform Technology IP mRNA with Defence’s Accum™ Program has Been Initiated 2022 Breakthrough Results: Defence Novel Accutex™ Intranasal Reduced 50% of Cancer Nodules on Aon Animals with Lung Tumors Defence’s mRNA with Accum™ for Cancer Vaccines Update Defence positioned to begin its anti-cancer Accutox™ phase i trial with successful completion of GLP studies Defence’s successfull study on the accuvac-pt007 vaccine targeting cervical cancer Defence Therapeutics completes fully-subscribed debenture financing of $2,355,000 Defence to apply its propriatry Accum™ technology in The design of messenger RNA anti-cancer vaccines Defence therapeutics announces debenture financing Defence Therapeutics initiates lung cancer treatment program with its novel accutox™ formulation via intranasal Defence therapeutics is granted patents in Japan and Israel expanding its novel ADC platform technology in the fast growing antibody-drug conjugates market Breakthrough results with accum™ A1 reprogrammed MSC, Mesenchymal stem cells, in a novel vaccine cured 80% of animals with pre-established lymphoma Defence Therapeutics applauds United States President Biden cancer Moonshot initiative BREAKTHROUGH DISCOVERY: Defence Accum™ Variant "A1" converts mesenchymal stromal cells into potent antigen presenting cells suitable for cancer vaccination Defence Therapeutics receives U.S. patent covering its ADC platform technology BREAKTHROUGH DISCOVERY: Accutox™ effective kills cancer cells by directly eliciting DNA damage Defence's Accum™ with antibody drug conjugates (ADC) in development against cancer Defence reports effective control of cervical cancer growth in response to its ACCUVACC-PT007 Therapeutic Vaccination Defence's novel ACCUVAC-PTE7 vaccine shows complete protection from cervical cancer Defence Therapeutics announces issuance of a U.S. patent covering its pioneering vaccine platform technology Defence Therapeutics: An anti-cancer solutions platform company advancing its versatile Accum Technology Defence releases peer-reviewed publication of its preclinical data on ACCUVAC-D001L in cell reports medicine journal Defence retains CATO SMS to advise on its Phase I clinical trial on ACCUTOX™ for breast cancer Defence’s AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9 Defence Therapeutics achieves a major milestone and begins IND-enabling testing of its accutox lead compound against breast cancer 2021 Defence therapeutics reports successful completion of its covid-19 vaccine accuvac-pt001 toxicology studies in rabbits Defence therapeutics appoints dr. Riam shammaa to its board of directors Defence therapeutics development program to engineer a new hpv vaccine initiated Defence therapeutics receives dtc eligibility Defence therapeutics signs a collaboration agreement with the curie institute for testing the accum-t-dm1 adc therapeutic in pdx models of breast cancer Defence therapeutics, strong therapeutics pipeline: adc’s, cancer and covid vaccines Defence therapeutics advances in pre-clinical testing of its infectious disease vaccine program Defence therapeutics accumtm boosts by 9-fold the delivery effectiveness of the crispr/cas9 protein to target cells Defence therapeutics vaccines and program development Defence therapeutics cancer vaccine accuvac-d001 manufacturing targets melanoma and breast cancer Defence therapeutics accumtm variants in vitro study increases the potency of t-deruxtecan adc by 5-fold on breast cancer Defence therapeutics to finalize its objectives to initiate a phase i trial against breast cancer Defence therapeutics prepares for phase I trial to test its dc cancer vaccine, accuvac-d002, against melanoma Defence therapeutics successfully engineered and tested a novel intranasal covid-19 vaccine formulation in animals Defence therapeutics success in testing its covid-19 accuvac-pt001 vaccine in a non-rodent model Defence therapeutics files acid-based hydrogels usa provisional patent application Defence therapeutics selects the best 8 accumtm variants to optimize its adc therapeutic The antibody response induced by defence therapeutics accuvac-pt001 vaccine cross-reacts with all tested sars-cov-2 variants Defence therapeutics signs an agreement with biopharma excellence a pharmalex gmbh company, to maximize and strategize the development of its accumtm platform and clinical trials Defence therapeutics accutox exhibits potent anti-cancer properties Defence therapeutics retains the hus comprehensive cancer center to optimize its accum-t-dm1 adc therapeutic Defence therapeutics accuvac-d001 cancer vaccine generates effective long-lasting anti-tumoral response
